A recent study has found that using a combination of adalimumab and methotrexate can significantly lower treatment failure rates in pediatric Crohn’s disease patients. The study, which was conducted by a team of researchers in the Netherlands, found that the combination therapy lowered treatment failure rates by 2-fold when compared to patients treated with adalimumab alone.

Crohn’s disease is a chronic inflammatory bowel disease that can cause abdominal pain, diarrhea, weight loss, and fatigue. It is a particularly challenging condition for pediatric patients, as the disease can have a significant impact on growth and development.

The study’s lead author, Dr. Marleen van de Ven, notes that the results are promising for improving treatment outcomes for pediatric Crohn’s patients. “The combination therapy of adalimumab and methotrexate should be considered as a first-line treatment option in pediatric Crohn’s disease patients,” she says.

Overall, the study underscores the importance of exploring combination therapies to improve treatment outcomes for pediatric Crohn’s patients.

Read more: https://www.healio.com/news/gastroenterology/20230420/adalimumab-plus-methotrexate-lowers-treatment-failure-2fold-in-pediatric-crohns